DC-T cell axis is an effective target for treating non-small
cell lung cancer
Shuangcui Wang1,2,Guan Zhang1,2,Qian
Cui1,2,Yanjie Yang1,2,Dong
Wang1,2, Aqing Liu1,2,Ying
Xia1,2,Wentao Li1, Yunhe
Liu1, Jianchun Yu1*
1. Department of Oncology, First Teaching Hospital of Tianjin University
of Traditional Chinese Medicine, Tianjin, China
2. National Clinical Research Center for Chinese Medicine Acupuncture
and Moxibustion, Tianjin, China
Shuangcui Wang, E-mail:2778761272@qq.com
Guan Zhang, E-mail:1483950415@qq.com
Qian Cui, E-mail:cuiqian1025@163.com
Yanjie Yang, E-mail:1026790005@qq.com
Dong Wang, E-mail: 1632016659@qq.com
Aqing Liu, E-mail:8liuxiangyu8@163.com
Ying Xia, E-mail:1151364753@qq.com
Wentao Li, E-mail:v23liwentao@163.com
Yunhe Liu,E-mail:yunhe654321@126.com
Jianchun Yu,E-mail:yujianchun2000@163.com
Corresponding authors: Jianchun Yu
Correspondence: Jianchun Yu,Department of Oncology, First
Teaching Hospital of Tianjin University of Traditional Chinese Medicine,
Tianjin University of Traditional Chinese Medicine, Tianjin, China.
*Corresponding author.
Abstract: The DC-T cell axis is a bridge connecting innate
immunity and adaptive immunity. The initial immune response against
tumors is mainly induced by mature antigen-presenting dendritic cells
(DC). Enhancing the crosstalk between DC and T cells could improve the
immune response to non-small cell lung cancer. This article reviews the
interaction between DC-T cells in the treatment of non-small cell lung
cancer and how this interaction impacts the treatment outcome.
Keywords: non-small cell lung cancer; dendritic cells; T cells;
Artificial DC; Chimeric Antigen Receptor T-Cell Immunotherapy.